Intratumoral injection of LNP-formulated mIL12 (MEDI1191) induced tumor regression in superficial and deep-seated lesion models, with upregulation of CD8+ T-cell infiltration and IFN-γ expression. The gene discussed is CD8A; the disease is neoplasm.